肺表面活性物质的临床应用进展

中国临床药理学与治疗学 ›› 2010, Vol. 15 ›› Issue (7): 832-835.

肺表面活性物质的临床应用进展

徐国成, 李志奇

皖南医学院弋矶山医院儿科, 芜湖 241001,安徽

收稿日期:2010-03-25 修回日期:2010-04-22 出版日期:2010-07-26 发布日期:2020-09-15
作者简介:徐国成,男,主任医师,研究方向:儿科学。Tel: 13695671918 E-mail: xgcyjs@sohu.com

Clinical application advancement of pulmonary surfactant

XU Guo-cheng, LI Zhi-qi

Department of Pediatrics, Wannan Medical College Affiliated Yijishan Hospital, Wuhu 241001,Anhui, China

Received:2010-03-25 Revised:2010-04-22 Online:2010-07-26 Published:2020-09-15

摘要/Abstract

摘要： 肺泡表面活性物质是II型肺泡上皮细胞合成的一种磷脂-蛋白复合物,具有降低肺泡表面张力、维持肺泡稳定性、减少肺泡中液体外渗、预防肺水肿、促进气道的清除功能、抑制支气管收缩及增加肺免疫功能、减轻炎症反应、提高肺抗感染能力等多种作用。天然肺泡表面活性物质和合成肺泡表面活性物质制剂经气管注人或雾化吸人,临床治疗原发性肺泡表面活性物质缺乏性疾病及各种继发性肺泡表面活性物质缺乏相关性疾病具有一定疗效。

关键词: 肺泡表面活性物质, 呼吸窘迫综合征, 胎粪吸入综合征

Abstract: Pulmonary surfactant is a type of a phospholipid - protein complexes synthesized by II alveolar epithelial cells. It has many functions as decreasing alveolar surface tension to maintain alveolar stability, reducing alveolar fluid extravasation in the prevention of pulmonary edema, promoting the clearance of inlet ability, inhibiting bronchoconstriction and increasing the pulmonary immune function, reducing the inflammation and improving the lung anti-infection. The natural and synthetic surfactant preparations have some therapeutic effects on the clinical treatment of primary pulmonary surfactant deficiency disease and various secondary pulmonary surfactant-related diseases through tracheal injection or inhalation.

Key words: Pulmonary surfactant(PS), Respiratory distress syndrome(RDS), Meconium aspiration syndrome(MAS)

中图分类号:

徐国成, 李志奇. 肺表面活性物质的临床应用进展[J]. 中国临床药理学与治疗学, 2010, 15(7): 832-835.

XU Guo-cheng, LI Zhi-qi. Clinical application advancement of pulmonary surfactant[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(7): 832-835.

参考文献

[1] Cole FS, Nogee LM, Hamvas A. Defects in surfactant synthesis: clinical implications [J]. Pediatr Clin North Am,2006,53(5):911-927.
[2] Halliday HL. Surfactants:past, present and future[J]. J Perinatol,2008,28 Suppl 1:S47-S56.
[3] Hane F, Moores B, Amrein M, et al. Effect of SP-C on surface potential distribution in pulmonary surfactant: Atomic force microscopy and Kelvin probe force microscopy study[J]. Ultramicroscopy,2009,109(8):968-973.
[4] Dahl M, Holmskov U, Husby S, et al. Surfactant protein D levels in umbilical cord blood and capillary blood of premature infants. The influence of perinatal factors[J]. Pediatr Res,2006,59(6):806-810.
[5] Engle WA, American Academy of Pediatrics Committee on Fetus and Newborn.Surfactant-replacement therapy for respiratory distress in the preterm and term neonate [J]. Pediatrics, 2008,121(2):419-432.
[6] Cogo PE, Zimmermann LJ, Pesavento R, et al. Surfactant kinetics in preterm infants on mechanical ventilation who did and did not develop broncho pulmonary dysplasia[J]. Crit Care Med, 2003, 31(5):1532-1538.
[7] Minowa H, Takahashi Y, Kawaguchi C, et al. Expression of intrapulmonary surfactant apoprotein-A in autopsied Lungs: comparative study of cases with or without pulmonary hypoplasia[J]. Pediatr Res, 2000,48(5):674-678.
[8] Halliday HL. Recent clinical trials of surfactant treatment for neonates[J]. Biol Neonate, 2006,89(4):323-329.
[9] 新生儿呼吸疾病研究协作组.猪肺表面活性物质治疗胎粪吸入综合征的多中心随机对照研究[J].中华儿科杂志,2005,43(5):354-359.
[10] 吴丽燕.不同方式注入肺表面活性物质的疗效观察[J].现代医院,2009,1(9):24-26.
[11] Amizuka T, Shimizu H, Niida Y,et al. Surfactants therapy in neonates with respiratory failure due to haemorrhagic pulmonary oedema[J].Eur J Pediatr,2003,162(10):697-702.
[12] 戴芸佳.肺泡表面活性物质治疗新生儿呼吸窘迫综合征[J].中国新生儿科杂志,2007,22(3):172-173.
[13] 林静. 肺泡表面活性物质预防和治疗新生儿呼吸窘迫综合征疗效评价[J]. 中国热带医学,2004,4(6):1017-1019.
[14] 刘秀香,肖昕,熊爱华,等.合成及天然肺表面活性剂治疗新生儿呼吸窘迫综合征效果和安全性的Meta分析[J].临床儿科杂志,2004,22 (9):630-632.
[15] Yeh TF, Lin HC, Chang CH, et al. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. [J]. Pediatrics, 2008,121(5):e1310-1318.
[16] 杨杰,宁岑,覃安志,等.早产儿转运前应用肺表面活性物质的临床意义探讨[J]. 中国围产医学杂志,2006,9(1):28-31.
[17] 毕仲江,解福平,周伯香.肺表面活性物质预防新生儿呼吸窘迫综合症[J].南华大学学报,2008,36(4):530-531.
[18] Kakinuma R, Shimizu H, Ogawa Y.Effect of meconium on the rate of in vitro subtype conversion of swine pulmonary surfactant [J].Eur J Pediatr, 2002,161(1):1-36.
[19] Stevens TP, Sinkin RA. Surfactant replacement therapy [J].Chest,2007,131(5):1577-1582.
[20] Lacaze-Masmonteil T. Expanded Use of Surfactant Therapy in newborns[J]. Clin Perinatol, 2007,34(1):179-189.
[21] Been JV, Zimmermann LJ. What is new in surfactant.A clinical view on recent developments in neonatology and paediatrics [J].Eur J Pediatr,2007,166(9):889-899.
[22] 蔡及明,杨艳敏.应用外源性肺泡表面活性物质治疗小儿肺损伤的进展[J].上海医学,2004,27(8):618-620.